Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma

NCT02965157 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B-Cell

Interventions

BIOLOGICAL: CART20

Sponsor

Beijing Biohealthcare Biotechnology Co.,Ltd